Grazia Arpino1, Monica Milano2, Sabino De Placido2. 1. Università di Napoli Federico II, Napoli, Italy. Electronic address: grazia.arpino@unina.it. 2. Università di Napoli Federico II, Napoli, Italy.
Abstract
BACKGROUND: Aggressive breast cancer is a term commonly used in literature to describe breast cancer with a poor prognosis. Identifying and understanding the factors associated with aggressiveness could be helpful to the management of patients with breast cancer. Breast cancer is a heterogeneous disease, both clinically and biologically, which may be responsible for the wide range of survival durations for patients with metastatic disease. AIM: The goal of this study was to identify the factors most often described in association with aggressive metastatic breast cancer (MBC). METHODS: A systematic review was performed by querying PubMed from January 1, 2012 to June 1, 2014 for "metastatic breast cancer" ("aggressive" or "poor prognosis" or "high risk"). The level of evidence to support each potential prognostic factor of aggressive MBC was also reviewed. RESULTS: The identified factors were grouped into 3 principle categories: clinical, biological, and patient related. Because patient-related factors may not be indicative of inherent cancer aggressiveness, this review focused only on clinical and biological factors. The factors with the highest levels of evidence to support associations with survival in metastatic breast cancer were visceral metastases, number of metastatic sites, disease-free interval, presence of CTCs, triple-negative disease, and tumour grade. CONCLUSION: Identification of these factors and understanding their contribution to the aggressiveness of MBC and disease progression may lead to more personalized treatment in this patient population.
BACKGROUND:Aggressive breast cancer is a term commonly used in literature to describe breast cancer with a poor prognosis. Identifying and understanding the factors associated with aggressiveness could be helpful to the management of patients with breast cancer. Breast cancer is a heterogeneous disease, both clinically and biologically, which may be responsible for the wide range of survival durations for patients with metastatic disease. AIM: The goal of this study was to identify the factors most often described in association with aggressive metastatic breast cancer (MBC). METHODS: A systematic review was performed by querying PubMed from January 1, 2012 to June 1, 2014 for "metastatic breast cancer" ("aggressive" or "poor prognosis" or "high risk"). The level of evidence to support each potential prognostic factor of aggressive MBC was also reviewed. RESULTS: The identified factors were grouped into 3 principle categories: clinical, biological, and patient related. Because patient-related factors may not be indicative of inherent cancer aggressiveness, this review focused only on clinical and biological factors. The factors with the highest levels of evidence to support associations with survival in metastatic breast cancer were visceral metastases, number of metastatic sites, disease-free interval, presence of CTCs, triple-negative disease, and tumour grade. CONCLUSION: Identification of these factors and understanding their contribution to the aggressiveness of MBC and disease progression may lead to more personalized treatment in this patient population.
Authors: Lusine Yaghjyan; Rulla M Tamimi; Kimberly A Bertrand; Christopher G Scott; Matthew R Jensen; V Shane Pankratz; Kathy Brandt; Daniel Visscher; Aaron Norman; Fergus Couch; John Shepherd; Bo Fan; Yunn-Yi Chen; Lin Ma; Andrew H Beck; Steven R Cummings; Karla Kerlikowske; Celine M Vachon Journal: Breast Cancer Res Treat Date: 2017-06-17 Impact factor: 4.872
Authors: Zhenzhen Zhang; Fred K Tabung; Qi Jin; Grace Curran; Veronica L Irvin; Jackilen Shannon; Ellen M Velie; JoAnn E Manson; Michael S Simon; Mara Vitolins; Celina I Valencia; Linda Snetselaar; Sonali Jindal; Pepper Schedin Journal: Nutr Cancer Date: 2022-04-26 Impact factor: 2.816
Authors: Jennifer C Melvin; Wahyu Wulaningsih; Zac Hana; Arnie D Purushotham; Sarah E Pinder; Ian Fentiman; Cheryl Gillett; Anca Mera; Lars Holmberg; Mieke Van Hemelrijck Journal: Cancer Med Date: 2016-01-22 Impact factor: 4.452